医学
安慰剂
不利影响
系统性红斑狼疮
内科学
随机对照试验
红斑狼疮
蛋白尿
强的松
临床试验
免疫学
疾病
抗体
肾
替代医学
病理
作者
Richard Furie,Ian N Bruce,Thomas Dörner,Manuel Gustavo Leon,Piotr Leszczyński,Murray B. Urowitz,Birgit Haier,Teri Jimenez,Claire Brittain,Jiajun Liu,Catherine Barbey,C. Stach
出处
期刊:Rheumatology
[Oxford University Press]
日期:2021-05-05
卷期号:60 (11): 5397-5407
被引量:82
标识
DOI:10.1093/rheumatology/keab381
摘要
Abstract Objective To evaluate the dose–response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE. Methods Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A or ≥2 BILAG B domain scores), receiving stable CS (≤40 mg/day prednisone-equivalent), antimalarial or immunosuppressant drugs were included. Patients with stable LN (proteinuria ≤2 g/day) not receiving high-dose CS or CYC were permitted entry. Randomized patients received placebo or i.v. DZP (6/24/45 mg/kg) and standard-of-care (SOC) treatment every 4 weeks to week 24, after which patients received only SOC to week 48. The primary objective was to establish a dose–response relationship based on week 24 BILAG-Based Composite Lupus Assessment (BICLA) responder rates. Results All DZP groups exhibited improvements in clinical and immunological outcomes vs placebo at week 24; however, BICLA responder rates did not fit pre-specified dose–response models [best-fitting model (Emax): P = 0.07]. Incidences of serious treatment-emergent adverse events across DZP groups were low and similar to placebo. Following DZP withdrawal, SLEDAI-2K, physician’s global assessment (PGA), BILAG, and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores stabilized; BICLA and SLE Responder Index (SRI-4) responder rates declined (likely due to interventions with disallowed escape medications), BILAG flares increased, and immunologic parameters returned towards baseline. Conclusions Although the primary objective was not met, DZP appeared to be well tolerated, and patients exhibited improvements across multiple clinical and immunological measures of disease activity after 24 weeks relative to placebo. The potential clinical benefit of DZP warrants further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI